Mural Oncology has completed a scheme of arrangement with XOMA Royalty, where XOMA will acquire the entire issued share capital of Mural. The transaction became effective on December 5, 2025, with share trading cancellation and shareholder consideration distribution expected soon.

Mural Oncology has received High Court approval for a scheme of arrangement where XOMA Royalty will acquire the entire share capital of Mural. The acquisition is expected to become effective on December 5, 2025, with Mural shares to be delisted from Nasdaq on December 4, 2025.

Mural Oncology announced the final details of its acquisition by XRA 5 Corp., a subsidiary of XOMA Royalty, with a total cash consideration of $2.035 per share. The acquisition is expected to close in early December 2025, subject to Irish High Court sanction.

Mural Oncology shareholders voted to approve an acquisition by XRA 5 Corp., a subsidiary of XOMA Royalty, with over 99% of votes cast in favor. The transaction values Mural at approximately $36.2 million and is expected to close in Q4 2025.

Halper Sadeh LLC is investigating potential securities law violations and fiduciary duty breaches related to recent sales/mergers involving Performant Healthcare, Aris Water Solutions, and Mural Oncology.